Searched for:
(1 - 17 of 17)
document
Gaubius Instituut TNO (author), Nieuwenhuizen, W. (author), Vermond, A. (author), Nooijen, W.J. (author), Haverkate, F. (author)
Here the results obtained with human fibrinogen and its degradation products are reported. Our results differ from those obtained in (9) but strongly support model suggested earlier by us for Ca2(+)-binding by rat fibrinogen. Chemicals/CAS: calcium, 7440-70-2; fibrin, 9001-31-4; fibrinogen, 9001-32-5; Calcium, 7440-70-2; Fibrin, 9001-31-4;...
article 1979
document
Nieuwenhuizen, W. (author), Vermond, A. (author), Haverkate, F. (author), Gaubius instituut TNO (author)
Experiments have been carried out with fibrinogen and with purified degradation products of fibrinogen and fibrin which demonstrate that the structure of D fragments obtained after prolonged plasmin digestion is influenced by several factors in the media. The previously described protective effect of calcium ions on the ??-chain carboxy...
article 1981
document
Nieuwenhuizen, W. (author), Gravesen, M. (author), Gaubius instituut TNO (author)
Early plasmin degradation products (X fragments) of human fibrinogen were prepared in the presence of calcium-ions or EGTA, and purified on Sepharose 6B-CL. X fragments were characterized with respect to amino-terminal amino acids, polypeptide-chain composition, anticlotting properties and calcium-binding. Amino-terminal amino acids were alanine...
article 1981
document
Nieuwenhuizen, W. (author), Voskuilen, M. (author), Hermans, J. (author), Gaubius instituut TNO (author)
The present study was undertaken as a step to delineate further the localization of the calcium-binding sites in fibrinogen and to assess the anticlotting properties of fibrinogen degradation products. To this purpose, fragments Y were prepared by plasmin digestion of human fibrinogen in the presence of added Ca2+, and purified. We found that,...
article 1982
document
Verheijen, J.H. (author), Nieuwenhuizen, W. (author), Wijngaards, G. (author), Gaubius instituut TNO (author)
Tissue activator-mediated plasminogen activation is potentiated both by fibrin and by some soluble fibrin(ogen) fragments. The potentiating effect of the different fragments decreases in the order fibrin monomer > D-dimer > Y > D EGTA > Dcate > X. Fibrinogen and the fragments Ecate, E EGTA and E fibrin have almost no effect. The existence of a...
article 1982
document
Nieuwenhuizen, W. (author), Haverkate, F. (author), Gaubius Instituut TNO (author)
Chemicals/CAS: fibrinogen, 9001-32-5; calcium, 7440-70-2; Calcium, 7440-70-2; Fibrinogen, 9001-32-5
article 1983
document
Koppert, P.W. (author), Huijsmans, C.M.G. (author), Nieuwenhuizen, W. (author), Gaubius instituut TNO (author)
Spleen cells of BALB/c mice, immunized with fragments Y of normal human fibrinogen, were fused with P3 x 63 Ag 8653 myeloma cells. A clone was found which produces monoclonal antibodies (Mab-Y18) of the IgM?? type. Mab-Y18 is immunoreactive with normal human fibrinogen, and its fragments X, Y, N-terminal disulphide knot, A??-chain, and A??...
article 1985
document
Koppert, P.W. (author), Koopman, J. (author), Haverkate, F. (author), Nieuwenhuizen, W. (author), Gaubius instituut TNO (author)
Balb/c mice were immunized with a mixture of fibrin degradation products (XDPs) prepared by complete lysis of a human bloot clot by tissue-type plasminogen activator and purified by immunoaffinity chromatography. Spleen cells of the mice were fused with P3 x 63 Ag 8653 myeloma cells. A clone (FDP 14) was selected that produces monoclonal...
article 1986
document
Wasser, M.N.J.M. (author), Koppert, P.W. (author), Arndt, J.W. (author), Emeis, J.J. (author), Feitsma, R.I.J. (author), Pauwels, E.K.J. (author), Nieuwenhuizen, W. (author), Gaubius Instituut TNO (author)
Balb/c mice were immunized with human plasmin-generated fibrinogen degradation product Y. Spleen cells were fused with P3X63-Ag8.653 myeloma cells. A clone (Y22) was found that produces monoclonal antibodies (MoAbs) with a strong reactivity with human fibrin and only a weak reactivity with fibrinogen in an enzyme immunoassay (EIA). Y22 also...
article 1989
document
Nieuwenhuizen, W. (author), Traas, D.W. (author), Gezondheidsorganisatie TNO Gaubius instituut TNO (author)
At least four molecular forms of plasminogen are known. Two of those forms have glutamic acid at their amino-terminal end, and are designated as glu-plasminogen. The other two have lysine, methionine and/or valine as amino-terminal amino acid and are collectively designated as lys-plasminogen. Two subforms (I and II) each of glu- and lys...
article 1989
document
van Hinsbergh, V.W.M. (author), Bauer, K.A. (author), Kooistra, T. (author), Kluft, C. (author), Dooijewaard, G. (author), Sherman, M.L. (author), Nieuwenhuizen, W. (author), Gaubius instituut TNO (author)
Several investigators have reported that tumor necrosis factor (TNF) can alter the production of plasminogen activator type-1 (PAI-1) and plasminogen activators (PAs) by endothelial cells in vitro. We have examined the in vivo effects of recombinant human TNF administration on fibrinolysis as assessed by parameters in plasma during a 24-hour...
article 1990
document
Schielen, W.J.G. (author), Adams, H.P.H.M. (author), van Leuven, K. (author), Voskuilen, M. (author), Tesser, G.I. (author), Nieuwenhuizen, W. (author), Gaubius Instituut TNO (author)
Fibrin accelerates the activation of plasminogen catalyzed by tissue-type plasminogen activator much stronger than fibrinogen. Detailed studies showed that (part of) this rate-enhancing effect of fibrin is brought about by two sites in the fibrin molecule: one in Aα-(148-160) and one in the γ-chain stretch 311-379 (also known as FCB-5). During...
article 1991
document
Gaubius Instituut TNO (author), Atsma, D.E. (author), Kempen, H.J.M. (author), Nieuwenhuizen, W. (author), van 't Hooft, F.M. (author), Pauwels, E.K.J. (author)
Four 99mTc and three 123I labeling methods were evaluated for their suitability to label low density lipoproteins (LDL) for the purpose of scintigraphic biodistribution studies. For 99mTc these methods were: direct incorporation in LDL of 99mTcO4- using sodium dithionite (dithionite method); a method using first N,N-dimethylformamide to prepare...
article 1991
document
Bos, R. (author), Nieuwenhuizen, W. (author), Instituut voor Verouderings- en Vaatziekten Onderzoek TNO (author)
article 1992
document
Nieuwenhuizen, W. (author), Gaubius Laboratory Instituut voor verouderings- en vaatziekten onderzoek TNO (author)
Increased plasma levels of soluble fibrin are considered as molecular markers of an impending thrombotic event. Several methods to assess soluble fibrin have been in existence for many years. Most of those methods are nonspecific, semiquantitative or too laborious to be used in clinical practice. More recent methods are quantitative and...
article 1993
document
Bos, R. (author), Revet, M. (author), Nieuwenhuizen, W. (author), Gaubius Laboratory TNO Preventie en Gezondheid (author)
This article describes a two-step bio-immuno assay (BIA), which determines active (free) tissue-type plasminogen activator (t-PA) in (acidified) plasma. Plasma samples, diluted in buffer of pH 6.0, are added to the wells of a microtiter plate containing an immobilised monoclonal antibody which binds t-PA without affecting t-PA activity. After an...
article 1994
document
Nieuwenhuizen, W. (author), TNO Preventie en Gezondheid (author)
Fibrinogen is a large heterogeneous family of closely related molecules consisting of three pairs of non-identical polypeptide chains: two Aα-, two Bβ- and two γ-chains, held together by disulphide bridges. The heterogeneity of fibrinogen is due to heterogeneities in all three chains. Four main types of assay are used to determine fibrinogen...
article 1995
Searched for:
(1 - 17 of 17)